See the DrugPatentWatch profile for keytruda

Keytruda (pembrolizumab) is a cancer immunotherapy medication used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer. While it has shown significant efficacy in treating these cancers, it is not without its side effects. As with any medication, the side effects of Keytruda can change over time with prolonged use.

According to the FDA-approved label [1], the most common side effects of Keytruda include fatigue, decreased appetite, and itching. However, as patients continue to take the medication, they may experience a range of side effects, including:

1. Immune-mediated adverse reactions: Keytruda can cause immune-mediated reactions, such as hypophysitis (inflammation of the pituitary gland), adrenal insufficiency, and thyroiditis [2]. These reactions can occur at any time during treatment and may be severe.
2. Infusion reactions: Some patients may experience infusion reactions, which can range from mild to severe and may include symptoms such as fever, chills, and nausea [3].
3. Increased risk of infections: Keytruda can weaken the immune system, making patients more susceptible to infections. Patients may experience respiratory infections, urinary tract infections, and skin infections [4].
4. Neurological side effects: Some patients may experience neurological side effects, such as seizures, tremors, and peripheral neuropathy [5].
5. Endocrine side effects: Keytruda can cause endocrine side effects, including hypothyroidism, hyperthyroidism, and adrenal insufficiency [6].

It is essential to note that the frequency and severity of these side effects can vary depending on the individual patient and the duration of treatment. Patients taking Keytruda should closely monitor their health and report any side effects to their healthcare provider.

According to DrugPatentWatch.com, the patent for Keytruda is set to expire in 2028 [7]. This means that generic versions of the medication may become available, potentially leading to increased competition and potentially lower prices.

In conclusion, while Keytruda is a powerful cancer treatment, it is essential for patients to be aware of the potential side effects and to work closely with their healthcare provider to manage these effects. As with any medication, it is crucial to weigh the benefits and risks of treatment and to closely monitor health during prolonged use.

Sources:

[1] FDA. (2014). Pembrolizumab (Keytruda) Prescribing Information.

[2] Merck & Co., Inc. (2019). Keytruda (pembrolizumab) [Prescribing Information].

[3] Merck & Co., Inc. (2019). Keytruda (pembrolizumab) [Prescribing Information].

[4] Merck & Co., Inc. (2019). Keytruda (pembrolizumab) [Prescribing Information].

[5] Merck & Co., Inc. (2019). Keytruda (pembrolizumab) [Prescribing Information].

[6] Merck & Co., Inc. (2019). Keytruda (pembrolizumab) [Prescribing Information].

[7] DrugPatentWatch.com. (n.d.). Pembrolizumab (Keytruda) Patent Expiration.

Note: The sources cited are the FDA-approved label, the prescribing information provided by Merck & Co., Inc., and DrugPatentWatch.com.